Polaryx Therapeutics (PLYX) FDA Approvals $3.60 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$3.60 +0.00 (+0.14%) As of 05/22/2026 07:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share FDA Events Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock Polaryx Therapeutics' Drug in the FDA Approval ProcessThis section highlights FDA-related milestones and regulatory updates for drugs developed by Polaryx Therapeutics (PLYX). Over the past two years, Polaryx Therapeutics has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as PLX-200. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. PLX-200 FDA Regulatory Events PLX-200 is a drug developed by Polaryx Therapeutics for the following indication: For Treatment Of Late-Infantile Neuronal Ceroid Lipofuscinosis. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy. Designation Grant - April 21,2026Designation Grant Fast TrackDrug: PLX-200Announced Date: April 21, 2026Indication: For Treatment Of Late-Infantile Neuronal Ceroid LipofuscinosisAnnouncementPolaryx Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to PLX-200 for the treatment of Juvenile Neuronal Ceroid Lipofuscinosis (JNCL/CLN3 disease), Krabbe disease (globoid cell leukodystrophy), and Sandhoff disease (GM2 gangliosidosis Type II).AI SummaryPolaryx Therapeutics announced that the U.S. Food and Drug Administration has granted Fast Track Designation (FTD) to PLX-200 for the treatment of Juvenile Neuronal Ceroid Lipofuscinosis (JNCL/CLN3 disease), Krabbe disease (globoid cell leukodystrophy), and Sandhoff disease (GM2 gangliosidosis Type II). These are rare, serious genetic disorders that cause progressive neurodegeneration in children. PLX-200 is being developed to address the underlying disease processes, and these FTD decisions apply to its study in the company’s planned SOTERIA Phase 2 basket trial covering these indications. The Fast Track program is intended to speed development and review of drugs for serious conditions with unmet medical need. Companies with FTD often get more frequent contact with the FDA and may be eligible for rolling review of a future marketing application. Those features can help shorten development timelines and potentially bring treatments to patients sooner.Read AnnouncementDesignation Grant - March 17,2026Designation Grant Fast TrackDrug: PLX-200Announced Date: March 17, 2026Indication: For Treatment Of Late-Infantile Neuronal Ceroid LipofuscinosisAnnouncementPolaryx Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to PLX-200 for the treatment of Late-Infantile Neuronal Ceroid Lipofuscinosis (LINCL/CLN2 disease).AI SummaryPolaryx Therapeutics announced that the U.S. Food and Drug Administration has granted Fast Track Designation to PLX-200 for the treatment of Late-Infantile Neuronal Ceroid Lipofuscinosis (LINCL/CLN2 disease). Fast Track is meant to help speed the development and review of drugs for serious conditions with unmet medical needs. The designation can allow more frequent communication with the FDA and may enable a rolling review of a future marketing application, which could shorten the time to reach patients if trials are successful. This regulatory milestone supports Polaryx’s SOTERIA Phase 2 basket trial, an open-label, single-arm study testing PLX-200’s safety, tolerability, and clinical activity across four rare lysosomal storage disorders: CLN2, CLN3, Krabbe disease, and Sandhoff disease. The Fast Track status may help advance the program as the company continues clinical development. Read Announcement Polaryx Therapeutics FDA Events - Frequently Asked Questions Has Polaryx Therapeutics received FDA approval? As of now, Polaryx Therapeutics (PLYX) has not received any FDA approvals for its therapy in the last two years. What drugs has Polaryx Therapeutics submitted to the FDA? In the past two years, Polaryx Therapeutics (PLYX) has reported FDA regulatory activity for PLX-200. What is the most recent FDA event for Polaryx Therapeutics? The most recent FDA-related event for Polaryx Therapeutics occurred on April 21, 2026, involving PLX-200. The update was categorized as "Designation Grant," with the company reporting: "Polaryx Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to PLX-200 for the treatment of Juvenile Neuronal Ceroid Lipofuscinosis (JNCL/CLN3 disease), Krabbe disease (globoid cell leukodystrophy), and Sandhoff disease (GM2 gangliosidosis Type II)." What conditions do Polaryx Therapeutics' current drugs treat? Currently, Polaryx Therapeutics has one therapy (PLX-200) targeting the following condition: For Treatment Of Late-Infantile Neuronal Ceroid Lipofuscinosis. More FDA Event Resources from MarketBeat FDA Calendars Recent FDA Drug Approval Calendar Upcoming FDA Events & PDUFA Dates Calendar Companies With Recent FDA Events AC Immune FDA EventsAgios Pharmaceuticals FDA EventsAssembly Biosciences FDA EventsBriacell Therap FDA EventsBioLineRx FDA EventsFibroBiologics FDA EventsGilead Sciences FDA EventsOncolytics Biotech FDA EventsRegeneron Pharmaceuticals FDA EventsAbbVie FDA EventsMerck & Co., Inc. FDA EventsAgenus FDA EventsAdagio Medical FDA EventsAktis Oncology FDA EventsAkari Therapeutics FDA Events FDA Event Stage Terminology & Abbreviation Guide NDA: New Drug Application ANDA: Abbreviated New Drug Application sNDA: Supplemental New Drug Application BLA: Biologics License Application sBLA: Supplemental Biologics License Application FDA Approved: Approved by the FDA EMA: European Medicines Agency CE Mark: European Union Certification NMPA: China National Medical Products Administration MHLW: Japanese Ministry of Health FDA Meeting: Consultation with FDA Pre-IND: Pre-Investigational New Drug Meeting Breakthrough Therapy: Special FDA designation for promising therapies Fast Track: Accelerated FDA approval pathway Orphan Drug: Designation for rare disease treatments RPD: Rare Pediatric Disease Designation RMAT: Regenerative Medicine Advanced Therapy DSMB Review: Data Safety Monitoring Board Review IDMC Review: Independent Data Monitoring Committee MAA: MHRA Marketing Authorization Application RTF: Refusal to File (Rejected Application) 510(k): FDA Clearance for Medical Devices Rolling Submission: Staggered regulatory review process Related Companies Ocugen FDA Events Upstream Bio FDA Events Fulcrum Therapeutics FDA Events Lyell Immunopharma FDA Events PureTech Health FDA Events Evolus FDA Events Eupraxia Pharmaceuticals FDA Events Century Therapeutics FDA Events ADC Therapeutics FDA Events Autolus Therapeutics FDA Events Stock Lists Biotechnology StocksCompare Biotech StocksCompare Healthcare StocksCompare Pharmaceutical StocksHealthcare and Medical Stocks FDA progress for NASDAQ:PLYX last updated on 4/21/2026 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Polaryx Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Polaryx Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Designation Grant - April 21,2026Designation Grant Fast TrackDrug: PLX-200Announced Date: April 21, 2026Indication: For Treatment Of Late-Infantile Neuronal Ceroid LipofuscinosisAnnouncementPolaryx Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to PLX-200 for the treatment of Juvenile Neuronal Ceroid Lipofuscinosis (JNCL/CLN3 disease), Krabbe disease (globoid cell leukodystrophy), and Sandhoff disease (GM2 gangliosidosis Type II).AI SummaryPolaryx Therapeutics announced that the U.S. Food and Drug Administration has granted Fast Track Designation (FTD) to PLX-200 for the treatment of Juvenile Neuronal Ceroid Lipofuscinosis (JNCL/CLN3 disease), Krabbe disease (globoid cell leukodystrophy), and Sandhoff disease (GM2 gangliosidosis Type II). These are rare, serious genetic disorders that cause progressive neurodegeneration in children. PLX-200 is being developed to address the underlying disease processes, and these FTD decisions apply to its study in the company’s planned SOTERIA Phase 2 basket trial covering these indications. The Fast Track program is intended to speed development and review of drugs for serious conditions with unmet medical need. Companies with FTD often get more frequent contact with the FDA and may be eligible for rolling review of a future marketing application. Those features can help shorten development timelines and potentially bring treatments to patients sooner.Read Announcement
Designation Grant - March 17,2026Designation Grant Fast TrackDrug: PLX-200Announced Date: March 17, 2026Indication: For Treatment Of Late-Infantile Neuronal Ceroid LipofuscinosisAnnouncementPolaryx Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to PLX-200 for the treatment of Late-Infantile Neuronal Ceroid Lipofuscinosis (LINCL/CLN2 disease).AI SummaryPolaryx Therapeutics announced that the U.S. Food and Drug Administration has granted Fast Track Designation to PLX-200 for the treatment of Late-Infantile Neuronal Ceroid Lipofuscinosis (LINCL/CLN2 disease). Fast Track is meant to help speed the development and review of drugs for serious conditions with unmet medical needs. The designation can allow more frequent communication with the FDA and may enable a rolling review of a future marketing application, which could shorten the time to reach patients if trials are successful. This regulatory milestone supports Polaryx’s SOTERIA Phase 2 basket trial, an open-label, single-arm study testing PLX-200’s safety, tolerability, and clinical activity across four rare lysosomal storage disorders: CLN2, CLN3, Krabbe disease, and Sandhoff disease. The Fast Track status may help advance the program as the company continues clinical development. Read Announcement
